Synthesis, Physicochemical Properties and Biological Evaluation of Aromatic Ester Prodrugs of 1-(2‘-Hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): Orally Active Iron Chelators with Clinical Potential
- 1 May 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 51 (5) , 555-564
- https://doi.org/10.1211/0022357991772655
Abstract
The synthesis of seven aromatic ester derivatives of 1-(2′-hydroxyethyl)-2-ethyl-3-hydro-xypyridin-4-one is described. These ester prodrugs have been designed to target iron chelators to the liver, the major iron storage organ. In principle this should improve chelation efficacy and minimize toxicity. The distribution coefficients of these ester prodrugs between 1-octanol and MOPS buffer pH 7·4 were measured together with their rates of hydrolysis at pH 2 and pH 7·4, in rat blood and liver homogenate. Esters with heteroaromatic acid moieties were found to be less stable than benzoyl analogues. The in-vivo iron mobilisation efficacy of these ester prodrugs has been compared with that of the parent drug using a 59Fe-ferritin loaded rat model. Many prodrugs were found to enhance the ability of the parent hydroxypyridinone to facilitate 59Fe excretion. However, not all prodrugs provided increased efficacy, demonstrating that lipophilicity is not the only factor which influences drug efficacy. Furthermore, no clear correlation between efficacy and susceptibility to hydrolysis was detected. The picolinic and nicotinic ester derivatives appear to offer the best potential as prodrugs as they have a relatively low LogP value and yet lead to enhanced efficacy over the parent hydroxypyridinone.Keywords
This publication has 19 references indexed in Scilit:
- In vivo iron mobilisation evaluation of hydroxypyridinones in 59Fe-ferritin-loaded rat modelBiochemical Pharmacology, 1999
- Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermediaBlood, 1992
- Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in childrenScandinavian Journal of Clinical and Laboratory Investigation, 1992
- CARNITINE DEFICIENCY INDUCED BY PIVAMPICILLIN AND PIVMECILLINAM THERAPYThe Lancet, 1989
- Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemiaJournal of Inherited Metabolic Disease, 1988
- Pivampicillin-promoted excretion of pivaloylcarnitine in humansBiochemical Pharmacology, 1987
- Treatment of Inborn Errors of Urea SynthesisNew England Journal of Medicine, 1982
- The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural ProductsSynthesis, 1981
- NEW PATHWAYS OF NITROGEN EXCRETION IN INBORN ERRORS OF UREA SYNTHESISThe Lancet, 1979
- Drug Biotransformation Interactions in Man II: A Pharmacokinetic Study of the Simultaneous Conjugation of Benzoic and Salicylic Acids with GlycineJournal of Pharmaceutical Sciences, 1969